Syndivia is focused on unlocking the full therapeutic potential of antibody-drug conjugates by restoring the antibody as an active driver of efficacy, rather than treating it as a passive payload carrier. GeminiMab ADC platform allows conjugation while preserving antibody exposure close to that of the unconjugated backbone, enabling dosing levels where antibody biology is fully expressed.